NASDAQ:MDGL

Madrigal Pharmaceuticals (MDGL) Stock Forecast, Price & News

$142.02

-4.02 (-2.75%)

(As of 11:09 AM ET)

Compare

Today's Range: $141.33
▼
$146.04
50-Day Range: $146.04
▼
$210.63
52-Week Range: $57.21
▼
$322.67

Volume: 144,997 shs
Average Volume: 373,225 shs
Market Capitalization: $2.62 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $309.18

Madrigal Pharmaceuticals MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.82 Rating Score
Upside/Downside: 117.7% Upside
$309.18 Price Target
Short Interest: Bearish
16.46% of Float Sold Short
Dividend Strength: N/A
Sustainability: -0.92
Upright™ Environmental Score
News Sentiment: 0.81
Based on 9 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($18.87) to ($12.58) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.61 out of 5 stars

Medical Sector

93rd out of 969 stocks

Pharmaceutical Preparations Industry

29th out of 453 stocks

4.4

Analyst's Opinion

Consensus Rating
Madrigal Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.82, and is based on 9 buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $309.18, Madrigal Pharmaceuticals has a forecasted upside of 117.7% from its current price of $142.02.
Amount of Analyst Coverage
Madrigal Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

1.0

Short Interest

Percentage of Shares Shorted
16.46% of the float of Madrigal Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Madrigal Pharmaceuticals has a short interest ratio ("days to cover") of 6.3.
Change versus previous month
Short interest in Madrigal Pharmaceuticals has recently increased by 8.67%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Madrigal Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Madrigal Pharmaceuticals does not have a long track record of dividend growth.

4.6

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Madrigal Pharmaceuticals has received a 73.28% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Preclinical research services for physical health" products. See details.
Environmental Sustainability
The Environmental Impact score for Madrigal Pharmaceuticals is -0.92.

2.7

News and Social Media Coverage

News Sentiment
Madrigal Pharmaceuticals has a news sentiment score of 0.81. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.69 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Madrigal Pharmaceuticals this week, compared to 3 articles on an average week.
Search Interest
Only 15 people have searched for MDGL on MarketBeat in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
MarketBeat Follows
Only 6 people have added Madrigal Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -14% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Madrigal Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
23.92% of the stock of Madrigal Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
79.86% of the stock of Madrigal Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Madrigal Pharmaceuticals are expected to grow in the coming year, from ($18.87) to ($12.58) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Madrigal Pharmaceuticals is -7.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Madrigal Pharmaceuticals is -7.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Madrigal Pharmaceuticals has a P/B Ratio of 12.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor beta agonist, which is in Phase III clinical trials for treating NASH. The company is also developing MGL-3745, a backup compound to resmetirom. The company is headquartered in West Conshohocken, Pennsylvania.

MDGL Price History

30 days | 90 days | 365 days | Advanced Chart

MDGL Stock News Headlines

October 1, 2023 | americanbankingnews.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up to $151.69

September 29, 2023 | finanznachrichten.de

Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Announces Proposed Public Offering

October 2, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

According to FX Empire, the gold forecast is now bullish, with support for a $3,000 target in 2024. The big question is how to play it. Some investors are discovering a unique gold investment alternative that sidesteps the major issues with gold mining stocks or physical gold.

September 29, 2023 | markets.businessinsider.com

Madrigal Pharma Announces Pricing Of $500 Mln Public Offering - Quick Facts

September 29, 2023 | bizjournals.com

Montgomery County biopharma firm plans $500M stock offering while FDA reviews its NASH treatment application

September 29, 2023 | finance.yahoo.com

Madrigal Pharmaceuticals Announces Pricing of $500 Million Public Offering

September 28, 2023 | finance.yahoo.com

Madrigal Pharmaceuticals Announces Proposed Public Offering

September 27, 2023 | finance.yahoo.com

Wall Street Thinks Madrigal Pharmaceuticals Could Climb 93%. Here's Why It Could Happen Soon.

October 2, 2023 | Edge On The Street (Ad)

Gold Could Be Heading for Record Highs - But How to Play It?

September 27, 2023 | americanbankingnews.com

Head to Head Survey: Madrigal Pharmaceuticals (NASDAQ:MDGL) & Milestone Pharmaceuticals (NASDAQ:MIST)

September 21, 2023 | msn.com

Obesity treatment optimism boosts Eli Lilly, Novo Nordisk while others face downturn

September 20, 2023 | finance.yahoo.com

1 Beaten-Down Stock That Could Soar by 86%, According to Wall Street

September 19, 2023 | msn.com

Evercore ISI Group Maintains Madrigal Pharmaceuticals (MDGL) Outperform Recommendation

September 15, 2023 | finanznachrichten.de

Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 14, 2023 | finance.yahoo.com

Madrigal Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

September 13, 2023 | msn.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Jumps on Move to the Head of the FDA Line

September 13, 2023 | marketwatch.com

Madrigal Gets FDA Priority Review of Resmetirom in NASH With Liver Fibrosis >MDGL

September 13, 2023 | finance.yahoo.com

Madrigal Pharmaceuticals Announces NDA Acceptance and Priority Review of the New Drug Application for Resmetirom for the Treatment of NASH with Liver Fibrosis

September 13, 2023 | finance.yahoo.com

Madrigal Pharmaceuticals Surges As Its NASH Treatment Toes The Long-Awaited Finish Line

September 11, 2023 | markets.businessinsider.com

The Latest Analyst Ratings for Madrigal Pharmaceuticals

September 11, 2023 | finanznachrichten.de

Madrigal Pharmaceuticals, Inc.: Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer

September 11, 2023 | benzinga.com

Madrigal Pharmaceuticals Appoints Bill Sibold as Chief Executive Officer

September 7, 2023 | finance.yahoo.com

3 Biotech Stocks That Wall Street Analysts Can’t Get Enough Of

September 1, 2023 | markets.businessinsider.com

B.Riley Financial Sticks to Its Hold Rating for Madrigal Pharmaceuticals (MDGL)

August 23, 2023 | finance.yahoo.com

3 Biotechs Compete for the Same $108-Billion-Dollar Market. Are They a Buy?

August 20, 2023 | msn.com

Madrigal's Resmetirom Nears Commercialization Despite Market Concerns

August 14, 2023 | finance.yahoo.com

John Paulson's Q2 2023 13F Filing Update

See More Headlines

Receive MDGL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Madrigal Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

MDGL Company Calendar

Last Earnings: 8/08/2023
Today: 10/02/2023
Next Earnings (Estimated): 11/02/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Biotechnology
Sector: Medical
Current Symbol: NASDAQ:MDGL
CUSIP: 87162T20
CIK: 1157601
Web: www.madrigalpharma.com
Phone: (267) 824-2827
Fax: 781-274-8228
Employees: 92
Year Founded: 2011

Price Target and Rating

Average Stock Price Forecast: $309.18
High Stock Price Forecast: $390.00
Low Stock Price Forecast: $224.00
Forecasted Upside/Downside: +111.7%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.82
Research Coverage: 11 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($18.65)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-295,350,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -285.72%
Return on Assets: -114.11%

Debt

Debt-to-Equity Ratio: 0.96
Current Ratio: 3.02
Quick Ratio: 3.02

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $11.54 per share
Price / Book: 12.66

Miscellaneous

Outstanding Shares: 18,470,000
Free Float: 14,053,000
Market Cap: $2.70 billion
Optionable: Optionable
Beta: -0.72

Social Links

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Rebecca A. Taub M.D. (Age 71)
Founder, Chief Medical Officer, Pres of R&D and Director
Comp: $939.83k

Mr. Alex G. Howarth (Age 54)
Sr. VP & CFO
Comp: $757.26k

Mr. Brian J. Lynch J.D. (Age 61)
Sr. VP & Gen. Counsel
Comp: $763.75k

Mr. Remy Sukhija (Age 51)
Sr. VP & Chief Commercial Officer
Comp: $785.2k

Mr. William J. Sibold (Age 57)
CEO & Director

Dr. Kianoush Motesharei Ph.d. (Age 53)
Sr. VP of Bus. & Corp. Devel.

Mr. Edward Chiang
Sr. VP of Clinical & Technical Operations

Mr. Thomas W. Hare
Sr. VP of Clinical Management

Dr. Robert E. Waltermire Ph.D. (Age 59)
Chief Pharmaceutical Devel. Officer

Dr. Stephen Dodge M.B.A.
Pharm.D., Sr. VP of Global Medical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MDGL Stock - Frequently Asked Questions

Should I buy or sell Madrigal Pharmaceuticals stock right now?: 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Madrigal Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" MDGL shares.
View MDGL analyst ratings or view top-rated stocks.
What is Madrigal Pharmaceuticals' stock price forecast for 2023?: 11 equities research analysts have issued 12 month target prices for Madrigal Pharmaceuticals' shares. Their MDGL share price forecasts range from $224.00 to $390.00. On average, they anticipate the company's stock price to reach $309.18 in the next year. This suggests a possible upside of 111.7% from the stock's current price.
View analysts price targets for MDGL or view top-rated stocks among Wall Street analysts.
How have MDGL shares performed in 2023?: Madrigal Pharmaceuticals' stock was trading at $290.25 on January 1st, 2023. Since then, MDGL stock has decreased by 49.7% and is now trading at $146.04.
View the best growth stocks for 2023 here.
When is Madrigal Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our MDGL earnings forecast.
How were Madrigal Pharmaceuticals' earnings last quarter?: Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) released its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($4.69) EPS for the quarter, missing analysts' consensus estimates of ($4.59) by $0.10.
What ETFs hold Madrigal Pharmaceuticals' stock?: ETFs with the largest weight of Madrigal Pharmaceuticals (NASDAQ:MDGL) stock in their portfolio include Simplify Propel Opportunities ETF (SURI), Alger Mid Cap 40 ETF (FRTY), Principal Healthcare Innovators ETF (BTEC) and iShares U.S. Pharmaceuticals ETF (IHE).Invesco Nasdaq Biotechnology ETF (IBBQ).

What other stocks do shareholders of Madrigal Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Madrigal Pharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Exelixis (EXEL), Ayala Pharmaceuticals (ADXS), Viking Therapeutics (VKTX), Sangamo Therapeutics (SGMO), Amarin (AMRN), CRISPR Therapeutics (CRSP), Intercept Pharmaceuticals (ICPT), Sarepta Therapeutics (SRPT) and Gilead Sciences (gild).
What is Madrigal Pharmaceuticals' stock symbol?: Madrigal Pharmaceuticals trades on the NASDAQ under the ticker symbol "MDGL."
How do I buy shares of Madrigal Pharmaceuticals?: Shares of MDGL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Madrigal Pharmaceuticals' stock price today?: One share of MDGL stock can currently be purchased for approximately $146.04.
How much money does Madrigal Pharmaceuticals make?: Madrigal Pharmaceuticals (NASDAQ:MDGL) has a market capitalization of $2.70 billion. The biopharmaceutical company earns $-295,350,000.00 in net income (profit) each year or ($18.65) on an earnings per share basis.
How can I contact Madrigal Pharmaceuticals?: Madrigal Pharmaceuticals' mailing address is 200 BARR HARBOR DRIVE SUITE 400, WEST CONSHOHOCKEN PA, 19428. The official website for the company is www.madrigalpharma.com. The biopharmaceutical company can be reached via phone at (267) 824-2827, via email at ir@madrigalpharma.com, or via fax at 781-274-8228.

This page (NASDAQ:MDGL) was last updated on 10/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial